Multifunctional nanoplatform addresses three key barriers to effective TNBC immunotherapy

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15-20% of all cases.

Read Original Copy